ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS SOLUBLE RECEPTOR TYPE 2 IN PATIENTS WITH EXUDATIVE PSORIASIS

Download full text PDF
Issue: 
11
Year: 
2017

Professor Yu. Perlamutrov, MD; T. Aivazova, Candidate of Medical Sciences A.I. Evdokimov Moscow State University of Medicine and Dentistry

The paper considers information on the pathogenesis of psoriasis, the specific features of angiogenesis in patients with psoriasis. The baseline serum levels of free vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-R2) were determined in patients with exudative psoriasis and in apparently healthy individuals (a control group). A correlation analysis was carried out to assess an association between the baseline levels of VEGF, sVEGF-R2 in the serum of patients with exudative psoriasis, Psoriasis Area and Severity Index (PASI), patient age, and a VEGF/sVEGF-R2 ratio.
Keywords: 
dermatology
psoriasis
angiogenesis
vascular endothelial growth factor
soluble vascular endothelial growth factor receptor

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Bakston P.K. Dermatologija / M.: Izdatel'stvo BINOM, 2006; s. 18–28.
  2. Weigle N., McBane S. Psoriasis // Am. Fam. Physician. – 2013; 87 (9): 626–33.
  3. Olisova O.Ju., Tepljuk N.P., Pinegin V.B. Sovremennye metody lechenija psoriaza // RMZh. – 2015; 9: 483.
  4. Hebif T. Kozhnye bolezni: Diagnostika i lechenie / M.: MEDpress-inform, 2007; s. 114–23.
  5. Tolmacheva N.V., Anisimova A.S. Sovremennyj vzgljad na etiologiju i patogenez psoriaza // Fund. issled. – 2015; 1 –10: 2118–21.
  6. Mattotstsi K., Salvi M., D’Epiro S. i dr. Rol' reguljatornyh T-kletok v patogeneze psoriaza: obzor literatury // RMZh. – 2016; 10: 642–50.
  7. Skripkin Ju.K., Bogush P.G., Kruglova L.S. i dr. Novye vozmozhnosti naruzhnoj terapii psoriaza // Vestn. dermatol. i venerol. – 2006; 3: 33–6.
  8. Carmeliet P., Ferreira V., Breier G. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele // Nature. – 1996; 380: 435–9.
  9. Risau W. et al. Platelate-derived growth factor is angiogenic in vivo // Growth factors. – 1997; 7: 261–6.
  10. Shalaby F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice // Nature. – 1995; 376: 62–6.
  11. Pankov Ju.A. Gormony – reguljatory zhizni v sovremennoj molekuljarnoj endokrinologii // Biohimija. – 1998; 63 (12): 1600–15.
  12. Ferrara N., Dans-Smyth T. The biology of vascular endothelial growth factor // Endocrine Revs. – 1997; 18: 4–23.
  13. Alieva S.K. Klinicheskoe znachenie faktora rosta endotelija sosudov pri rake molochnoj zhelezy. Dis. … kand. med. nauk. M., 2003; s. 12–20.
  14. Ferrara N., Carver-Moore K., Chen H. et al. Heterozigous embrionic lethality induced by targeted inactivation of the VEGF gene // Nature. – 1996; 380: 439–42.
  15. Kushlinskij N.E., Gershtejn E.S. Rol' faktora rosta endotelija sosudov pri rake molochnoj zhelezy // Bjull. eksperim. biologii i meditsiny. – 2002; 133 (6): 604–12.
  16. Hyder S., Murthy L., Stancel G. Progestin Regulation of Vascular Endothelial Growth Factor in Human Breast Cancer Cells // Cancer Res. – 1998; 58 (3): 392–5.
  17. Reynolds K., Farzaneh F., Collins W. et al. Association of ovarian malignancy with expression of platelate-derived endothelial cell growth factor // J. Natl Cancer Inst. – 1994; 86: 1234–8.